FDA Inspection 1071709 — Novel Laboratories, Inc. d.b.a Lupin Somerset

Novel Laboratories, Inc. d.b.a Lupin Somerset — FEI 3006271438

The FDA completed an inspection of Novel Laboratories, Inc. d.b.a Lupin Somerset on November 8, 2018 in Somerset, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 3 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
November 8, 2018
Fiscal Year
2019
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Somerset, NJ (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)

Citations

IDCFRDescription
683121 CFR 314.80(c)(2)Late submission of quarterly safety reports
683221 CFR 314.80(c)(2)Late submission of annual safety reports
891221 CFR 314.81(b)(2)Timely submission